Quality of Life Debate
Vinay highlights a critical disconnect between quality of life measurements in cancer drug trials and the realities faced by patients in the real world, where financial burdens can drastically alter their experiences. The discussion emphasizes that while trials may measure quality of life under ideal conditions, they fail to account for the significant impact of drug costs on actual patient well-being. Russ adds that while extending life for the elderly is noble, the motivations behind drug interventions often skew the incentives for pharmaceutical companies, raising important ethical questions.In this clip
From this podcast
EconTalk
Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
Related Questions